Data suggest that a high expression of PD-L1 on tumour cells is associated with a superior response to treatment with ICI (Herbst et al. 2016; Gandini et al. 2016; Xia et al. 2019; Fehrenbacher et al. 2016; Gandhi et al. 2018). The gene discussed is CD274; the disease is neoplasm.